Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KBA 1413

Next Previous
Drug Profile

KBA 1413

Alternative Names: AT 1413 bivalent antibody immune therapeutic; AT1413; AT1413 BAIT; AT1413 bTCE; CD3-AT1413; KBA-1413

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AIMM Therapeutics
  • Developer Kling Biotherapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Malignant melanoma; Myelodysplastic syndromes

Most Recent Events

  • 03 Mar 2025 Pharmacodynamics data from a preclinical studies in Acute myeloid leukemia presented at the ESMO Targeted Anticancer Therapies Congress 2025, 2025 (TAT-2025)
  • 19 Dec 2023 KBA 1413 is still in preclinical development for Acute-myeloid-leukaemia in Netherlands (Parenteral) (Kling Biotherapeutics pipeline, December 2023)
  • 19 Dec 2023 KBA 1413 is still in preclinical development for Malignant-melanoma in Netherlands (Parenteral) (Kling Biotherapeutics pipeline, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top